Table 2.
Chemotherapy regimens at PCNSL presentation
| Treatment | Patients, no. |
|---|---|
| MTX-based | 27 |
| FAB/LMB-96 | 9 |
| Bonn protocol | 2 |
| CALGB-50202 | 1 |
| POG-9906 | 1 |
| COG-ANHL0131/A | 1 |
| IA-MTX/IV Cy + BBBD | 2 |
| Methotrexate (225 mg) + vincristine (2.5 mg) | 1 |
| Methotrexate/vincristine + other regimens# | 3 |
| HD-MTX (5 g/m2) + HD-Ara-C (3 g/m2) | 3 |
| HD-MTX (3.5–5 g/m2) + other chemotherapy drugs* | 4 |
| Non-MTX based | 2 |
| CCNU | 1 |
| Vincristine/prednisone/doxorubicin | 1 |
-FAB (French-American-British) LMB 96 = COPADM x 2: cyclophosphamide, vincristine, prednisone, cytarabine, doxorubicin, intravenous methotrexate (5–8 g/m2); CYVE x 2: cytarabine (3 g/m2), etoposide.
-Bonn protocol = methotrexate (3 g/m2), vincristine, ifosfamide, dexamethasone, intra-omaya chemotherapy, cytarabine (3g/m2) and vindesine.
-CALGB-50202: methotrexate (3.5 g/m2), rituximab, temozolomide, cytarabine, etoposide
-POG (pediatric oncology group) 9906-Acute lymphoblastic leukemia protocol: vincristine, prednisone, doxorubicin, L-asparaginase; cyclophosphamide, cytarabine, 6-mercaptopurine plus intrathecal methotrexate; intravenous methotrexate (5 g/m2), vincristine; oral 6-mercaptopurine plus oral methotrexate in maintenance. Patient received also 1200 cGy WBRT.
-COG (children’s oncology group) ANHL0131-regimen A-anaplastic T-large cell lymphoma protocol: vincristine, prednisone, L-asparaginase, doxorubicin plus intrathecal methotrexate; oral methotrexate plus 6-mercaptopurine/prednisone in maintenance.
-IA-MTX: intra-arterial methotrexate (1.5–2.5 g/m2) × 2 days, IV Cy: intravenous cyclophosphamide (15 mg/kg/day) × 2 days, BBBD: blood-brain-barrier disruption for a total 12 months
Other regimens included cyclophosphamide, doxorubicin, ifosfamide, cytarabine, and etoposide
Other chemotherapy drugs included thiotepa (35 mg/m2)/cytarabine (1), vincristine/procarbazine (1), vincristine/cyclophosphamide/dexamethasone (1), rituximab/ifosfamide/carboplatin/etoposide (1).